Emma Walmsley, who became CEO of drug giant GSK in 2017 after 17 years at L'Oreal, has led the company through several challenges: disappointing COVID-19 vaccine candidates, noise from activist investors, and Europe's largest demerger in two decades when the company spun out its consumer healthcare business. But according to Walmsley this all comes with the job. And, she also has a lot to celebrate. Shortly before she visited the Leadership Next studio, GSK announced its RSV vaccine was one of two recommended for approval by the FDA for older adults.
In this episode of Leadership Next, Walmsley talks to hosts Alan Murray and Michal Lev-Ram about the potential impact of that approval and the other aspects of GSK's infectious disease portfolio including innovation in H.I.V. treatment and prevention. She also shares her thoughts on the opportunities for data tech in healthcare, leading in the face of pushback from activist investors, and being the only woman CEO in big pharma.
Explore more of Fortune! Use the promo code LN25 to get 25% off an annual subscription at fortune.com/subscribe.
Leadership Next is Powered by Deloitte.